C4 Therapeutics was founded in 2015, originating out of pioneering scientific research from the Dana-Farber Cancer Institute. The company was established to commercialize advanced targeted protein degradation platforms before completing its initial public offering on the NASDAQ exchange in October 2020.
Cardiovascular diseases (such as ischemic heart disease and strokes) consistently rank as the leading cause of mortality in the United Arab Emirates. Other significant contributing factors to the national mortality profile include non-communicable lifestyle illnesses like diabetes, oncological conditions, and accidental injuries.